Web Exclusives

The rise of virtual business models in biopharma reflects the changing face of the pharmaceutical industry – big pharma discovering and developing its own pipeline exclusively in-house no longer exists.

Cliodhna McDonough says new regulations on the horizon for medical devices in Europe present a huge challenge to manufacturers, but could also deliver improved confidence in the consistency and effectiveness of the regulatory process.

The European Court should prepare for legal challenges to the ineligibility of new medical technologies for Supplementary Protection Certificates (SPCs).

In today’s highly competitive healthcare market how can pharma companies stand out from the crowd? Showing brand value has never been more important.

CRISPR has the potential to transform a variety of scientific areas, but this genome editing technique is also shrouded in controversy, particularly regarding its potential use to create genetically engineered humans.

The health of the life sciences sector in 2019 will continue to be a major focus as the UK navigates all the issues surrounding Brexit.

Saddam Huq, global QA senior manager, Distribution & Cold Chain, at GlaxoSmithKline, speaks to PharmaTimes about temperature excursions and managing the associated risks on a global scale.

The traditional pharma industry is eyeing the rise of Digital Therapeutics as patient outcomes fast become the only metric to sweat over. Their combined effect is setting the scene for a radical transformation of the industry. Its survival as a dominant force in shaping healthcare will depend on how it responds.

Excitement around the transformative potential of AI and machine learning continues to build. Companies will need to adapt their individual offers to draw in AI specialists, but as an industry UK pharma should also continue to champion itself and the unique career advantages it holds for the best and brightest researchers.

Professor Chris Whitty, chief scientific adviser for the Department of Health and Social Care (DHSC), on the role of the NIHR and the promise of the government’s second sector deal for the life sciences industry.

Mark Toms, chief scientific officer at Novartis Pharmaceuticals UK, looks at how to address the challenges of recruiting for Alzheimer’s prevention studies.

The escalating counterfeit problem in the pharmaceutical industry is causing damage to companies and putting lives at risk.

The 2018 Access to Medicines Index is encouraging and shows that the pharmaceutical industry continues to do more to improve access to medicine in low- and middle-income countries.